Windtree Announces Istaroxime Scientific Abstract Has Been Accepted at the 2023 Technology and Heart Failure Therapeutics Conference

The Company announced that its abstract entitled “Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients with Pre Cardiogenic Shock” has been accepted for presentation at the Technology and Heart Failure Therapeutics Conference (THT) being held on March 20-22, 2023 in Boston, MA.